CONTINUUS

ASPR's IBx Portfolio

Product: APIs in Final Dosage Form

Description of Project: CONTINUUS Pharmaceuticals Inc. will develop a domestic production capability for critical active pharmaceutical ingredients (APIs) and final dosage form medicines using their proprietary integrated continuous manufacturing (ICM) technology.

Unique Impact: ICM enables rapid, on-demand production of medicines from API to final dosage form without interruption in a fully-automated, small-footprint facility. CONTINUUS’ proprietary technology will also enable the establishment of a new manufacturing logistics capability, allowing more efficient delivery of medical countermeasures in future healthcare crises.  

Base Award Amount: $69,300,000.00

Category: Vaccine Supplies and Materials, Therapeutics Supplies and Raw Materials